120 related articles for article (PubMed ID: 3909805)
1. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
4. Teniposide is not effective in chronic lymphocytic leukemia.
Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
6. VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
Oishi N; Fleming TR; Laufman L; Ungerleider JS; Natale RB; Einstein AB; Von Hoff DD; Macdonald JS
Invest New Drugs; 1990 Feb; 8(1):93-5. PubMed ID: 2188930
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of VM-26 in adult malignancies.
Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
[No Abstract] [Full Text] [Related]
8. Teniposide in refractory ovarian cancer: a phase II study.
Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
[No Abstract] [Full Text] [Related]
9. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).
Cerny T; Pedrazzini A; Joss RA; Brunner KW
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1791-4. PubMed ID: 2850194
[TBL] [Abstract][Full Text] [Related]
10. Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Bundy BN; Given FT; Stehman FB
Am J Clin Oncol; 1990 Apr; 13(2):117-8. PubMed ID: 2316480
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Qazi R; Elson P; Khandekar JD
Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
[No Abstract] [Full Text] [Related]
12. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.
Pfeiffer P; Cold S; Bertelsen K; Panduro J; Sandberg E; Rose C
Gynecol Oncol; 1990 May; 37(2):230-3. PubMed ID: 2344968
[TBL] [Abstract][Full Text] [Related]
13. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
Bork E; Hansen M; Dombernowsky P; Hansen SW; Pedersen AG; Hansen HH
J Clin Oncol; 1986 Apr; 4(4):524-7. PubMed ID: 3007684
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
[No Abstract] [Full Text] [Related]
15. Use of VM-26 as a single agent in the treatment of renal carcinoma.
Hire EA; Samson MK; Fraile RJ; Baker LH
Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
[TBL] [Abstract][Full Text] [Related]
16. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
18. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
19. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
20. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
